J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report

seekingalpha09-15

With Johnson & Johnson (NYSE:JNJ) taking the lead, Big Pharma returned to dealmaking in H1 2024 even as the number of M&A deals in the life science sector dropped over the period, healthcare data ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467046391?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326622628/image_1326622628.jpg","is_english":true,"pubTime":"2024-09-15 03:37","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2467046391","market":"hk","top_or_hot":-1,"title":"J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report","media":"seekingalpha","content":"<div>\n<p>With Johnson & Johnson (NYSE:JNJ) taking the lead, Big Pharma returned to dealmaking in H1 2024 even as the number of M&A deals in the life science sector dropped over the period, healthcare data ...</p>\n\n<a href=\"https://seekingalpha.com/news/4149797-jj-leads-h1-2024-healthcare-dealmaking\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J leads H1 healthcare deals as Big Pharma dealmaking returns: report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-15 03:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4149797-jj-leads-h1-2024-healthcare-dealmaking><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With Johnson & Johnson (NYSE:JNJ) taking the lead, Big Pharma returned to dealmaking in H1 2024 even as the number of M&A deals in the life science sector dropped over the period, healthcare data ...</p>\n\n<a href=\"https://seekingalpha.com/news/4149797-jj-leads-h1-2024-healthcare-dealmaking\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0034235303.USD","symbol_name":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4149797-jj-leads-h1-2024-healthcare-dealmaking","article_id":"2467046391","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1326622628/image_1326622628.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467046391","pubTimestamp":1726342679,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"With Johnson & Johnson (NYSE:JNJ) taking the lead, Big Pharma returned to dealmaking in H1 2024 even as the number of M&A deals in the life science sector dropped over the period, healthcare data anal","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","03165":"华夏欧优股对冲","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4516":"特朗普概念","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4592":"伊斯兰概念","NVS":"诺华","PFE":"辉瑞","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","CTLT":"Catalent","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4585":"ETF&股票定投概念","MRK":"默沙东","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","RHHBY":"罗氏控股","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","JNJ":"强生","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4568":"美国抗疫概念","SNY":"赛诺菲安万特","BK4588":"碎股","ADC":"艾格里房产","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","IQV":"艾昆纬","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)"},"translate_title":"随着大型制药公司交易回归，强生引领上半年医疗保健交易：报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"SNY":1,"RHHBY":1,"NVS":1,"NVO":1,"MRK":1,"JNJ":1,"IQV":1,"CTLT":1,"PFE":0.7,"03165":0.6},"content_text":"With Johnson & Johnson (NYSE:JNJ) taking the lead, Big Pharma returned to dealmaking in H1 2024 even as the number of M&A deals in the life science sector dropped over the period, healthcare data analytics firm Iqvia (IQV) said in a report this week. Unveiling its Pharma Deals Half-Year Review, the contract research organization said that while the number of M&A deals announced by life science companies dropped 20% from H1 2023 to H1 2024, their median and mean values sharply increased.   However, the overall dealmaking activity remained muted during the period as macroeconomic uncertainties discouraged cautious dealmakers. The total value of all M&A deals signed during the period dropped 12% to $89.3B, including Pfizer’s (PFE) $43B agreement to acquire cancer drugmaker Seagen in Q1 2023. However, excluding the PFE-Seagen mega-merger, both mean and aggregate total deal value rose 54% YoY in H1, while the median deal value, which removes the effects of outliers, jumped 307%. Meanwhile, 23 M&A deals surpassed $1B in value, compared to only 15 a year ago. With 20 publicly announced deals, J&J (JNJ) became the top dealmaker during H1 2024, overtaking Merck (NYSE:MRK), the winner of H1 2023.  JNJ’s dealmaking activity was primarily focused on cancer and immunology, with the New Jersey-based healthcare giant adding antibody-drug conjugate (ADC) developer Ambrx Biopharma and bispecific antibody developers Proteologix and Yellow Jersey Therapeutics. Meanwhile, Merck’s (MRK) deal activity fell 19% in H1, with the cancer drugmaker opting for clinical trial collaborations and supply agreements related to its blockbuster anti-PD-1 therapy Keytruda in more than 50% of its 17 deals. European pharma majors Sanofi (NASDAQ:SNY), Novartis (NYSE:NVS), and Reche (OTCQX:RHHBY) took third, fourth, and fifth positions in H1 deal activity, respectively, while Novo Holdings, the investment arm of Novo Nordisk’s (NVO) controlling shareholder, claimed the top spot in M&A activity. With Novo (NVO) struggling to fulfill the demand for its weight loss products, Novo Holdings struck a $16.5B agreement in February to acquire contract manufacturer Catalent (CTLT), a deal expected to close by year-end.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467046391"}